Search
01/08/2021
Neural signatures of predictive language processing in Parkinson's disease with and without mild cognitive impairment
Leon-Cabrera, P, Pagonabarraga, J, Moris, J, Martinez-Horta, S, Marin-Lahoz, J, Horta-Barba, A, Bejr-Kasem, H, Kulisevsky, J, Rodriguez-Fornells, A. Neural signatures of predictive language processing in Parkinson's disease with and without mild cognitive impairment. CORTEX. 2021; 141DOI:10.1016/j.cortex.2021.03.032. PMID:34049254. IF:4.644(Q1/2D).
01/08/2021
Present and Future of Parkinson's Disease in Spain: PARKINSON-2030 Delphi Project
Garcia, DS, Blazquez-Estrada, M, Calopa, M, Escamilla-Sevilla, F, Freire, E, Ruiz, PJG, Grandas, F, Kulisevsky, J, Lopez-Manzanares, L, Castrillo, JCM, Mir, P, Pagonabarraga, J, Perez-Errazquin, F, Salom, JM, Tijero, B, Valldeoriola, F, Yanez, R, Aviles, A, Luquin, MR. Present and Future of Parkinson's Disease in Spain: PARKINSON-2030 Delphi Project. Brain Sciences. 2021; 11(8)DOI:10.3390/brainsci11081027. PMID:34439646. IF:3.333(Q3/7D).
01/08/2021
The role of glutamatergic neurotransmission in the motor and non-motor symptoms in Parkinson's disease: Clinical cases and a review of the literature
Pagonabarraga, J, Tinazzi, M, Caccia, C, Jost, WH. The role of glutamatergic neurotransmission in the motor and non-motor symptoms in Parkinson's disease: Clinical cases and a review of the literature. JOURNAL OF CLINICAL NEUROSCIENCE. 2021; 90DOI:10.1016/j.jocn.2021.05.056. PMID:34275546. IF:2.116(Q4/9D).
01/08/2021
The effect of family environment and psychiatric family history on psychosocial functioning in first-episode psychosis at baseline and after 2 years
Verdolini, N, Amoretti, S, Mezquida, G, Cuesta, MJ, Pina-Camacho, L, Garcia-Rizo, C, Lobo, A, Gonzalez-Pinto, A, Merchan-Naranjo, J, Corripio, I, Salagre, E, Baeza, I, Berge, D, Garriga, M, Bioque, M, Vallespir, C, Serra, M, Vieta, E, Bernardo, M. The effect of family environment and psychiatric family history on psychosocial functioning in first-episode psychosis at baseline and after 2 years. EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2021; 49DOI:10.1016/j.euroneuro.2021.03.015. PMID:33857739. IF:5.415(Q1/3D).
01/08/2021
Comparison of COVID-19 and Non-COVID-19 Pneumonia in Down Syndrome
de Asua, DR, Mayer, MA, Ortega, MD, Borrel, JM, Bermejo, TD, Gonzalez-Lamuno, D, Manso, C, Moldenhauer, F, Carmona-Iragui, M, Huls, A, Sherman, SL, Strydom, A, de la Torre, R, Dierssen, M, Spanish Trisomy 21 Res Soc COVID-1. Comparison of COVID-19 and Non-COVID-19 Pneumonia in Down Syndrome. Journal of Clinical Medicine. 2021; 10(16)DOI:10.3390/jcm10163748. PMID:34442043. IF:4.964(Q2/4D).
01/08/2021
Diagnostic and prognostic performance and longitudinal changes in plasma neurofilament light chain concentrations in adults with Down syndrome: a cohort study
Carmona-Iragui, M, Alcolea, D, Barroeta, I, Videla, L, Munoz, L, Van Pelt, KL, Schmitt, FA, Lightner, DD, Koehl, LM, Jicha, G, Sacco, S, Mircher, C, Pape, SE, Hithersay, R, Clare, ICH, Holland, AJ, Nubling, G, Levin, J, Zaman, SH, Strydom, A, Rebillat, AS, Head, E, Blesa, R, Lleo, A, Fortea, J. Diagnostic and prognostic performance and longitudinal changes in plasma neurofilament light chain concentrations in adults with Down syndrome: a cohort study. LANCET NEUROLOGY. 2021; 20(8)DOI:10.1016/S1474-4422(21)00129-0. PMID:34302785. IF:59.935(Q1/1D).